Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Positive early results for Sanofi bird flu vaccine
The preliminary results showed that the vaccine was safe and well-tolerated in 300 healthy volunteers. A 30 microgram dose with an adjuvant in a two-dose regimen demonstrated an
The preliminary results showed that the vaccine was safe and well-tolerated in 300 healthy volunteers. A 30 microgram dose with an adjuvant in a two-dose regimen demonstrated an
The product list includes a mixture of off-patent and patent-protected molecules with cumulative annual sales in the US of approximately $4.1 million, according to Glenmark. Pursuant to the
The submission is being made for satraplatin to be used in combination with prednisone as a second-line chemotherapy treatment for patients with hormone-refractory prostate cancer (HRPC). GCP Biotech
BGC20-0166 works by targeting two distinct mechanisms of serotonin signaling. BTG has advanced the compound from preclinical validation studies to the current clinical trial in less than eighteen
The recommendation is expected to be adopted by the European Commission in early 2006. EU orphan drug designation encourages the development of products to treat life-threatening or very
Factor VII is a natural protein with a pivotal role in blood coagulation and clotting. Uncontrolled bleeding is the most common cause of trauma mortality in the hospital
Protox plans to initiate phase I clinical trials of PRX302 early next year upon approval of the IND by the FDA. The trial is expected to enroll 18-24
The product is indicated for the treatment of community-acquired pneumonia and pelvic inflammatory disease, when caused by susceptible microorganisms. Sales of this product exceeded $69 million in 2004
The study will evaluate the safety and efficacy of CB7630 administered daily to patients with chemotherapy-naive hormone refractory prostate cancer (HRPC) with a rising PSA (prostate specific antigen)
The proposed merger is subject to approval of the stockholders of both ActivBiotics and Metaphore and is expected to close by the end of December or early January.